Topoisomerase II α Gene as a Marker for Prognostic Prediction of Hepatocellular Carcinoma: A Bioinformatics Analysis

To investigate the expression of topoisomerase II α (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. We used HCC-related datasets in UALCAN, HCCDB, and cBioPortal databases to analyze the expression and mutation of TOP2α and its co-expressed genes in HC...

Full description

Saved in:
Bibliographic Details
Published inChinese medical sciences journal Vol. 37; no. 4; pp. 331 - 339
Main Authors Lu, Jin, An, Shaoguang, Ma, Junjie, Yang, Yue, Zhang, Lei, Yu, Peng, Tao, Heng, Chen, Yunfan, Zhang, Haoxuan
Format Journal Article
LanguageEnglish
Published China Elsevier B.V 31.12.2022
Anhui Key Laboratory of Computational Medicine and Intelligent Health,Bengbu Medical College,Bengbu,Anhui 233030,China%Clinical Medical College,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Otolaryngology,First Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Surgical Oncology,Second Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China
School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China
Subjects
Online AccessGet full text

Cover

Loading…
Abstract To investigate the expression of topoisomerase II α (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. We used HCC-related datasets in UALCAN, HCCDB, and cBioPortal databases to analyze the expression and mutation of TOP2α and its co-expressed genes in HCC tissues. GO function and KEGG pathway enrichment of TOP2α and its co-expressed genes were identified. The TIMER database was used to analyze infiltration levels of immune cells in HCC. The impacts of TOP2α and its co-expression genes and the infiltrated immune cells on the survival of HCC patients were assayed by Kaplan-Meier plotter analysis. TOP2α and its co-expression genes were highly expressed in HCC (P < 0.001) and detrimental to overall survival of HCC patients (P < 0.001). TOP2α and its co-expression genes were mainly involved in cell mitosis and proliferation, and cell cycle pathway (ID: hsa04110, P = 0.00194S). TOP2α and its co-expression genes were mutated in HCC and the mutations were significantly detrimental to overall survival (P = 0.0247) and disease-free survival (P = 0.026S) of HCC patients. High TOP2α expression was positively correlated with the infiltration of B cell (r = 0.4S9, P < 0.01), CD8+T cell (r = 0.312, P < 0.01), CD4+T cell (r = 0.370, P < 0.01), macrophage (r = 0.459, P < 0.01), neutrophil (r = 0.405, P < 0.01), and dendritic cell (r = 0.473, P < 0.01) in HCC. The CD8+T cell infiltration significantly prolonged the 3- and 5-year survival of HCC patients (all P < 0.05), and CD4+T cell infiltration significantly shortened the 3-, 5-, and 10-year survival of HCC patients (all P < 0.05) TOP2α may be an oncogene, which was associated with poor prognosis of HCC patients and could be used as a biomarker for the prognostic prediction of HCC.
AbstractList Objective To investigate the expression of topoisomeraseⅡα (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. Methods We used HCC-related datasets in UALCAN, HCCDB, and cBioPortal databases to analyze the expression and mutation of TOP2α and its co-expressed genes in HCC tissues. GO function and KEGG pathway enrichment of TOP2α and its co-expressed genes were identified. The TIMER database was used to analyze infiltration levels of immune cells in HCC. The impacts of TOP2α and its co-expression genes and the infiltrated immune cells on the survival of HCC patients were assayed by Kaplan-Meier plotter analysis. Results TOP2α and its co-expression genes were highly expressed in HCC (P < 0.001) and detrimental to overall survival of HCC patients (P < 0.001). TOP2α and its co-expression genes were mainly involved in cell mitosis and proliferation, and cell cycle pathway (ID: hsa04110, P = 0.001945). TOP2α and its co-expression genes were mutated in HCC and the mutations were significantly detrimental to overall survival (P = 0.0247) and disease-free survival (P = 0.0265) of HCC patients. High TOP2α expression was positively correlated with the infiltration of B cell (r = 0.459, P < 0.01), CD8+ T cell (r = 0.312, P < 0.01), CD4+ T cell (r = 0.370, P < 0.01), macrophage (r = 0.459, P < 0.01), neutrophil (r = 0.405, P < 0.01), and dendritic cell (r = 0.473, P < 0.01) in HCC. The CD8+ T cell infiltration significantly prolonged the 3- and 5-year survival of HCC patients (all P < 0.05), and CD4+ T cell infiltration significantly shortened the 3-, 5-, and 10-year survival of HCC patients (all P < 0.05) Conclusion TOP2α may be an oncogene, which was associated with poor prognosis of HCC patients and could be used as a biomarker for the prognostic prediction of HCC.
Objective To investigate the expression of Ⅱ ( ) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. Methods We used HCC-related datasets in UALCAN, HCCDB, and cBioPortal databases to analyze the expression and mutation of and its co-expressed genes in HCC tissues. GO function and KEGG pathway enrichment of and its co-expressed genes were identified. The TIMER database was used to analyze infiltration levels of immune cells in HCC. The impacts of and its co-expression genes and the infiltrated immune cells on the survival of HCC patients were assayed by plotter analysis. Results and its co-expression genes were highly expressed in HCC ( < 0.001) and detrimental to overall survival of HCC patients ( < 0.001). and its co-expression genes were mainly involved in cell mitosis and proliferation, and cell cycle pathway (ID: hsa04110, = 0.001945). and its co-expression genes were mutated in HCC and the mutations were significantly detrimental to overall survival ( = 0.0247) and disease-free survival ( = 0.0265) of HCC patients. High expression was positively correlated with the infiltration of B cell ( = 0.459, < 0.01), CD8 T cell ( = 0.312, < 0.01), CD4 T cell ( = 0.370, < 0.01), macrophage ( = 0.459, < 0.01), neutrophil ( = 0.405, < 0.01), and dendritic cell ( = 0.473, < 0.01) in HCC. The CD8 T cell infiltration significantly prolonged the 3- and 5-year survival of HCC patients (all < 0.05), and CD4 T cell infiltration significantly shortened the 3-, 5-, and 10-year survival of HCC patients (all < 0.05). Conclusion may be an oncogene, which was associated with poor prognosis of HCC patients and could be used as a biomarker for the prognostic prediction of HCC.
Objective To investigate the expression of topoisomeraseⅡα (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. Methods We used HCC-related datasets in UALCAN, HCCDB, and cBioPortal databases to analyze the expression and mutation of TOP2α and its co-expressed genes in HCC tissues. GO function and KEGG pathway enrichment of TOP2α and its co-expressed genes were identified. The TIMER database was used to analyze infiltration levels of immune cells in HCC. The impacts of TOP2α and its co-expression genes and the infiltrated immune cells on the survival of HCC patients were assayed by Kaplan-Meier plotter analysis. Results TOP2α and its co-expression genes were highly expressed in HCC (P< 0.001) and detrimental to overall survival of HCC patients (P< 0.001). TOP2α and its co-expression genes were mainly involved in cell mitosis and proliferation, and cell cycle pathway (ID: hsa04110, P = 0.001945). TOP2α and its co-expression genes were mutated in HCC and the mutations were significantly detrimental to overall survival (P = 0.0247) and disease-free survival (P = 0.0265) of HCC patients. High TOP2α expression was positively correlated with the infiltration of B cell (r = 0.459, P< 0.01), CD8+ T cell (r = 0.312, P< 0.01), CD4+ T cell (r = 0.370, P< 0.01), macrophage (r = 0.459, P< 0.01), neutrophil (r = 0.405, P< 0.01), and dendritic cell (r = 0.473, P< 0.01) in HCC. The CD8+ T cell infiltration significantly prolonged the 3- and 5-year survival of HCC patients (all P< 0.05), and CD4+ T cell infiltration significantly shortened the 3-, 5-, and 10-year survival of HCC patients (all P< 0.05). ConclusionTOP2α may be an oncogene, which was associated with poor prognosis of HCC patients and could be used as a biomarker for the prognostic prediction of HCC.Objective To investigate the expression of topoisomeraseⅡα (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. Methods We used HCC-related datasets in UALCAN, HCCDB, and cBioPortal databases to analyze the expression and mutation of TOP2α and its co-expressed genes in HCC tissues. GO function and KEGG pathway enrichment of TOP2α and its co-expressed genes were identified. The TIMER database was used to analyze infiltration levels of immune cells in HCC. The impacts of TOP2α and its co-expression genes and the infiltrated immune cells on the survival of HCC patients were assayed by Kaplan-Meier plotter analysis. Results TOP2α and its co-expression genes were highly expressed in HCC (P< 0.001) and detrimental to overall survival of HCC patients (P< 0.001). TOP2α and its co-expression genes were mainly involved in cell mitosis and proliferation, and cell cycle pathway (ID: hsa04110, P = 0.001945). TOP2α and its co-expression genes were mutated in HCC and the mutations were significantly detrimental to overall survival (P = 0.0247) and disease-free survival (P = 0.0265) of HCC patients. High TOP2α expression was positively correlated with the infiltration of B cell (r = 0.459, P< 0.01), CD8+ T cell (r = 0.312, P< 0.01), CD4+ T cell (r = 0.370, P< 0.01), macrophage (r = 0.459, P< 0.01), neutrophil (r = 0.405, P< 0.01), and dendritic cell (r = 0.473, P< 0.01) in HCC. The CD8+ T cell infiltration significantly prolonged the 3- and 5-year survival of HCC patients (all P< 0.05), and CD4+ T cell infiltration significantly shortened the 3-, 5-, and 10-year survival of HCC patients (all P< 0.05). ConclusionTOP2α may be an oncogene, which was associated with poor prognosis of HCC patients and could be used as a biomarker for the prognostic prediction of HCC.
To investigate the expression of topoisomerase II α (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. We used HCC-related datasets in UALCAN, HCCDB, and cBioPortal databases to analyze the expression and mutation of TOP2α and its co-expressed genes in HCC tissues. GO function and KEGG pathway enrichment of TOP2α and its co-expressed genes were identified. The TIMER database was used to analyze infiltration levels of immune cells in HCC. The impacts of TOP2α and its co-expression genes and the infiltrated immune cells on the survival of HCC patients were assayed by Kaplan-Meier plotter analysis. TOP2α and its co-expression genes were highly expressed in HCC (P < 0.001) and detrimental to overall survival of HCC patients (P < 0.001). TOP2α and its co-expression genes were mainly involved in cell mitosis and proliferation, and cell cycle pathway (ID: hsa04110, P = 0.00194S). TOP2α and its co-expression genes were mutated in HCC and the mutations were significantly detrimental to overall survival (P = 0.0247) and disease-free survival (P = 0.026S) of HCC patients. High TOP2α expression was positively correlated with the infiltration of B cell (r = 0.4S9, P < 0.01), CD8+T cell (r = 0.312, P < 0.01), CD4+T cell (r = 0.370, P < 0.01), macrophage (r = 0.459, P < 0.01), neutrophil (r = 0.405, P < 0.01), and dendritic cell (r = 0.473, P < 0.01) in HCC. The CD8+T cell infiltration significantly prolonged the 3- and 5-year survival of HCC patients (all P < 0.05), and CD4+T cell infiltration significantly shortened the 3-, 5-, and 10-year survival of HCC patients (all P < 0.05) TOP2α may be an oncogene, which was associated with poor prognosis of HCC patients and could be used as a biomarker for the prognostic prediction of HCC.
Author Ma, Junjie
An, Shaoguang
Yu, Peng
Chen, Yunfan
Tao, Heng
Zhang, Haoxuan
Yang, Yue
Zhang, Lei
Lu, Jin
AuthorAffiliation School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China;Anhui Key Laboratory of Computational Medicine and Intelligent Health,Bengbu Medical College,Bengbu,Anhui 233030,China%Clinical Medical College,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Otolaryngology,First Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Surgical Oncology,Second Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China
AuthorAffiliation_xml – name: School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China;Anhui Key Laboratory of Computational Medicine and Intelligent Health,Bengbu Medical College,Bengbu,Anhui 233030,China%Clinical Medical College,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Otolaryngology,First Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Surgical Oncology,Second Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China
Author_xml – sequence: 1
  givenname: Jin
  surname: Lu
  fullname: Lu, Jin
  organization: School of Basic Medicine, Bengbu, Anhui 233030, China
– sequence: 2
  givenname: Shaoguang
  surname: An
  fullname: An, Shaoguang
  organization: Clinical Medical College; Bengbu Medical College, Bengbu, Anhui 233030, China
– sequence: 3
  givenname: Junjie
  surname: Ma
  fullname: Ma, Junjie
  organization: Clinical Medical College; Bengbu Medical College, Bengbu, Anhui 233030, China
– sequence: 4
  givenname: Yue
  surname: Yang
  fullname: Yang, Yue
  organization: Department of Otolaryngology, First Affiliated Hospital, Bengbu Medical College, Bengbu, Anhui 233030, China
– sequence: 5
  givenname: Lei
  surname: Zhang
  fullname: Zhang, Lei
  organization: Department of Surgical Oncology, Second Affiliated Hospital, Bengbu Medical College, Bengbu, Anhui 233030, China
– sequence: 6
  givenname: Peng
  surname: Yu
  fullname: Yu, Peng
  organization: School of Basic Medicine, Bengbu, Anhui 233030, China
– sequence: 7
  givenname: Heng
  surname: Tao
  fullname: Tao, Heng
  organization: School of Basic Medicine, Bengbu, Anhui 233030, China
– sequence: 8
  givenname: Yunfan
  surname: Chen
  fullname: Chen, Yunfan
  organization: School of Basic Medicine, Bengbu, Anhui 233030, China
– sequence: 9
  givenname: Haoxuan
  surname: Zhang
  fullname: Zhang, Haoxuan
  email: 0100197@bbmc.edu.cn
  organization: School of Basic Medicine, Bengbu, Anhui 233030, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36647592$$D View this record in MEDLINE/PubMed
BookMark eNptkc9u1DAQh30oon9AvAHyDS6BsZ04G27LqrQrFbWHcrZmnXHlJbEXOwH1sfoiPBNutwUJONmyvp9n5ptjdhBiIMZeCXgn607Ce4AaQB-wIwEgqk529SE7znkL5VUs6ufsUGldt00nj9h8HXfR5zhSwkx8veY_7_gZBeKYOfLPmL5S4i4mfpXiTYh58rZcqfd28jHw6Pg57XCKloZhHjDxFSbrQxzxA1_yjz76UNIjllzmy4DDbfb5BXvmcMj08vE8YV8-nV6vzquLy7P1anlRWQVKV1S3tV5oaEA4aKHVmxZ1bTvX9koosWg2WpSRZNcBNapTTU-bxuECnOgloVMn7M3-3x8YHIYbs41zKj1kY8e8NSRBygdZhXy7J3cpfpspT2b0-X4mDBTnbGRblCmhm6agrx_ReTNSb3bJj5huzZPUP1Vtijkncr8RAeZhRQaeqlZ_kdZPeC92SuiH__Biz1OR9t1TMtl6CrasI5GdTB_9P5lfeSWiEA
CitedBy_id crossref_primary_10_1186_s12967_024_05576_y
ContentType Journal Article
Copyright 2022 Chinese Academy Medical Sciences
Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: 2022 Chinese Academy Medical Sciences
– notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
CorporateAuthor 3蚌埠医学院 临床医学院, 安徽, 蚌埠 233030 3Clinical Medical College, Bengbu Medical College, Bengbu, Anhui 233030, China
4蚌埠医学院 第一附属医院耳鼻喉科, 安徽, 蚌埠 233030 4Department of Otolaryngology, First Affiliated Hospital, Bengbu Medical College, Bengbu, Anhui 233030, China
5蚌埠医学院 第二附属医院肿瘤外科, 安徽, 蚌埠 233030 5Department of Surgical Oncology, Second Affiliated Hospital, Bengbu Medical College, Bengbu, Anhui 233030, China
1蚌埠医学院 基础医学院, 安徽, 蚌埠 233030 1School of Basic Medicine, Bengbu Medical College, Bengbu, Anhui 233030, China
2蚌埠医学院 数字医学与智慧健康安徽省重点实验室, 安徽, 蚌埠 233030 2Anhui Key Laboratory of Computational Medicine and Intelligent Health, Bengbu Medical College, Bengbu, Anhui 233030, China
CorporateAuthor_xml – name: 1蚌埠医学院 基础医学院, 安徽, 蚌埠 233030 1School of Basic Medicine, Bengbu Medical College, Bengbu, Anhui 233030, China
– name: 5蚌埠医学院 第二附属医院肿瘤外科, 安徽, 蚌埠 233030 5Department of Surgical Oncology, Second Affiliated Hospital, Bengbu Medical College, Bengbu, Anhui 233030, China
– name: 4蚌埠医学院 第一附属医院耳鼻喉科, 安徽, 蚌埠 233030 4Department of Otolaryngology, First Affiliated Hospital, Bengbu Medical College, Bengbu, Anhui 233030, China
– name: 2蚌埠医学院 数字医学与智慧健康安徽省重点实验室, 安徽, 蚌埠 233030 2Anhui Key Laboratory of Computational Medicine and Intelligent Health, Bengbu Medical College, Bengbu, Anhui 233030, China
– name: 3蚌埠医学院 临床医学院, 安徽, 蚌埠 233030 3Clinical Medical College, Bengbu Medical College, Bengbu, Anhui 233030, China
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
2B.
4A8
92I
93N
PSX
TCJ
DOI 10.24920/004006
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
Pharmacy, Therapeutics, & Pharmacology
EndPage 339
ExternalDocumentID cmsj_e202204006
36647592
10_24920_004006
S100192942300007X
Genre Journal Article
GroupedDBID ---
--K
-05
-0E
-SE
-S~
.~1
0R~
1B1
1~.
1~5
29B
2B.
2C~
4.4
457
4G.
53G
5GY
5VR
5VS
5XA
5XF
5XL
7-5
71M
92F
92I
92M
93N
93R
9D9
9DE
AAEDT
AALRI
AAQFI
AAXUO
ABBQC
ABKZE
ADMUD
AEKER
AFTJW
AFUIB
AGYEJ
AITUG
AJRQY
ALMA_UNASSIGNED_HOLDINGS
CAJEE
CAJUS
CCEZO
CHBEP
CIEJG
CW9
DU5
EBS
EJD
EP2
EP3
FA0
FDB
FNPLU
GBLVA
HZ~
J1W
JUIAU
M41
MO0
N9A
O-L
O9-
OZT
P-8
P-9
PC.
Q--
Q-4
Q38
R-E
RIG
ROL
RT5
S..
SDF
SES
T8U
TCJ
TGQ
U1F
U1G
U5E
U5O
WFFXF
AAYXX
ABWVN
ACRPL
ADNMO
AIGII
CITATION
AAXDM
CGR
CUY
CVF
ECM
EIF
NPM
7X8
4A8
PSX
ID FETCH-LOGICAL-c3036-e4746860501f07076b7a64c9f7d313185b610612990e53935deb5fa80f1d2eaf3
IEDL.DBID .~1
ISSN 1001-9294
IngestDate Thu May 29 03:54:36 EDT 2025
Fri Jul 11 07:43:13 EDT 2025
Thu Jan 02 22:52:10 EST 2025
Tue Jul 01 01:55:48 EDT 2025
Thu Apr 24 22:54:23 EDT 2025
Fri Feb 23 02:38:27 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords overall survival
disease-free survival
topoisomerase II a
bioinformatics analysis
hepatocellular carcinoma
topoisomeraseⅡα
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3036-e4746860501f07076b7a64c9f7d313185b610612990e53935deb5fa80f1d2eaf3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://cmsj.cams.cn/CN/article/downloadArticleFile.do?attachType=PDF&id=3594
PMID 36647592
PQID 2766431655
PQPubID 23479
PageCount 9
ParticipantIDs wanfang_journals_cmsj_e202204006
proquest_miscellaneous_2766431655
pubmed_primary_36647592
crossref_primary_10_24920_004006
crossref_citationtrail_10_24920_004006
elsevier_sciencedirect_doi_10_24920_004006
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-Dec-31
PublicationDateYYYYMMDD 2022-12-31
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-Dec-31
  day: 31
PublicationDecade 2020
PublicationPlace China
PublicationPlace_xml – name: China
PublicationTitle Chinese medical sciences journal
PublicationTitleAlternate Chin Med Sci J
PublicationTitle_FL Chinese Medical Sciences Journal
PublicationYear 2022
Publisher Elsevier B.V
Anhui Key Laboratory of Computational Medicine and Intelligent Health,Bengbu Medical College,Bengbu,Anhui 233030,China%Clinical Medical College,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Otolaryngology,First Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Surgical Oncology,Second Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China
School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China
Publisher_xml – name: Elsevier B.V
– name: School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China
– name: Anhui Key Laboratory of Computational Medicine and Intelligent Health,Bengbu Medical College,Bengbu,Anhui 233030,China%Clinical Medical College,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Otolaryngology,First Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%Department of Surgical Oncology,Second Affliated Hospital,Bengbu Medical College,Bengbu,Anhui 233030,China%School of Basic Medicine,Bengbu Medical College,Bengbu,Anhui 233030,China
References Meyerovich, Goykhman, Nakache (bib137) 2019; 51
Liang, Zhu, Wang (bib134) 2019; 9
Huang, Wong, Tsui (bib138) 2019; 19
Almeida, René Gerhard, Dina Leitao (bib148) 2014; 210
Zhou, Li, Mao (bib146) 2019; 28
Schmidt (bib153) 2019; 3
Ji, Hu, Zhang (bib136) 2019; 11
Connell, Harding, Shia (bib143) 2016; 5
Sun, Yao, Song (bib144) 2017; 133
Visconti, Delia Monica, Grieco (bib150) 2016; 35
Utama, Patriawan (bib154) 2019; 7
Zeng, Liu, Dai (bib140) 2019; 19
Ghisoni, Maggiorotto, Borella (bib142) 2019; 12
Iwanaga (bib145) 2013; 40
Guillén, Prieto, Jiménez de Ory (bib152) 2019; 14
Rocha, Farias, Lima (bib139) 2019; 199
Nuncia-Cantarero, Martinez-Canales, Andrés-Pretel (bib141) 2018; 168
Dominguezbrauer, Thu, Mason (bib149) 2015; 60
Kang, Song, Du (bib151) 2016; 5
Skill, Butler, O’Brien (bib135) 2019; 51
Chen, Chien, Chen (bib147) 2017; 96
References_xml – volume: 51
  start-page: 1867
  year: 2019
  end-page: 1873
  ident: bib137
  article-title: Resection
  publication-title: Transplant Proc
– volume: 51
  start-page: 1907
  year: 2019
  end-page: 1912
  ident: bib135
  article-title: Financial burden of liver transplant
  publication-title: Transplant Proc
– volume: 19
  start-page: 789
  year: 2019
  ident: bib138
  article-title: Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma
  publication-title: BMC cancer
– volume: 35
  start-page: 153
  year: 2016
  ident: bib150
  article-title: Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
  publication-title: Clin Cancer Res
– volume: 210
  start-page: 675
  year: 2014
  end-page: 679
  ident: bib148
  article-title: Topoisomerase II-alfa gene as a predictive marker of response to anthracy-clines in breast cancer
  publication-title: Pathol Res Pract
– volume: 14
  start-page: e0220552
  year: 2019
  ident: bib152
  article-title: Prognostic factors of a lower CD4/CD8 ratio in long term viral suppression HIV infected children
  publication-title: PloS One
– volume: 96
  start-page: e5582
  year: 2017
  ident: bib147
  article-title: Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer
  publication-title: Medicine (Baltimore)
– volume: 40
  start-page: 1475
  year: 2013
  end-page: 1487
  ident: bib145
  article-title: Studies on cases of spontaneous regression of cancer in Japan in 2011, and of hepatic carcinoma, lung cancer and pulmonary metastases in the world between 2006 and 2011
  publication-title: Gan To Kagaku Ryoho
– volume: 199
  start-page: 110725
  year: 2019
  ident: bib139
  article-title: Computational studies, design and synthesis of Pd(II)-based complexes: allosteric inhibitors of the human topoisomerase-II
  publication-title: J Inorg Biochem
– volume: 11
  start-page: 4290
  year: 2019
  end-page: 4302
  ident: bib136
  article-title: Long non-coding RNA DSCAM-AS1 accelerates the progression of hepatocellular carcinoma
  publication-title: Am J Transí Res
– volume: 168
  start-page: 613
  year: 2018
  end-page: 623
  ident: bib141
  article-title: Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer
  publication-title: Breast Cancer Res Treat
– volume: 60
  start-page: 524
  year: 2015
  end-page: 536
  ident: bib149
  article-title: Targeting mitosis in cancer: emerging strategies
  publication-title: Mol Cell
– volume: 12
  start-page: 17
  year: 2019
  ident: bib142
  article-title: TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
  publication-title: J Ovarian Res
– volume: 5
  start-page: 66
  year: 2016
  ident: bib143
  article-title: Combined intrahepatic cholan-giocarcinoma and hepatocellular carcinoma
  publication-title: Chin Clin Oncol
– volume: 19
  start-page: 604
  year: 2019
  ident: bib140
  article-title: Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms
  publication-title: BMC cancer
– volume: 3
  start-page: 1
  year: 2019
  end-page: 12
  ident: bib153
  article-title: Identification of novel respiratory syncytial virus CD4 and CD8 T cell epitopes in C57BL/6 mice
  publication-title: Immunohorizons
– volume: 28
  start-page: 76S
  year: 2019
  end-page: 86S
  ident: bib146
  article-title: Screening hub genes as prognostic biomarkers of hepatocellular carcinoma by bioinformatics analysis
  publication-title: Cell Transplant
– volume: 5
  start-page: 17873
  year: 2016
  ident: bib151
  article-title: PTEN stabilizes TOP2A and regulates the DNA decatenation
  publication-title: Sci Rep
– volume: 133
  start-page: 1
  year: 2017
  end-page: 10
  ident: bib144
  article-title: Autophagy antagonizes apop-tosis induced by flavan enantiomers from Daphne giraldii in hepatic carcinoma cells
  publication-title: Eur J Med Chem
– volume: 7
  start-page: 1803
  year: 2019
  end-page: 1807
  ident: bib154
  article-title: Correlation of CD4/CD8 ratio with carotid intima-media layer thickness in HIV/AIDS patients at Sanglah General Hospital, Bali, Indonesia
  publication-title: Open Access Maced J Med Sci
– volume: 9
  start-page: 11580
  year: 2019
  ident: bib134
  article-title: Evaluation of AGP fucosylation as a marker for hepatocellular carcinoma of three different etiologies
  publication-title: Sci Rep
SSID ssj0006184
Score 2.2658508
Snippet To investigate the expression of topoisomerase II α (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. We used...
Objective To investigate the expression of Ⅱ ( ) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients. Methods We used...
Objective To investigate the expression of topoisomeraseⅡα (TOP2α) in hepatocellular carcinoma (HCC) and its role in predicting prognosis of HCC patients....
SourceID wanfang
proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 331
SubjectTerms bioinformatics analysis
Biomarkers, Tumor - genetics
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - genetics
CD8-Positive T-Lymphocytes
Computational Biology
disease-free survival
DNA Topoisomerases, Type II - genetics
hepatocellular carcinoma
Humans
Liver Neoplasms - diagnosis
Liver Neoplasms - genetics
overall survival
Prognosis
topoisomerase II a
Title Topoisomerase II α Gene as a Marker for Prognostic Prediction of Hepatocellular Carcinoma: A Bioinformatics Analysis
URI https://dx.doi.org/10.24920/004006
https://www.ncbi.nlm.nih.gov/pubmed/36647592
https://www.proquest.com/docview/2766431655
https://d.wanfangdata.com.cn/periodical/cmsj-e202204006
Volume 37
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NitswEBbLwpZeSjf9S9stUyg5lHUTO7Jk720JXbKFLYFmITchyVJJ6VohTg659J36In2mamR50xJ66M3YsiU0o5mRNd83hLyjqWa24joZF1onNLN-zSmqk7TyvppKZYtQzufmM5ve0k-LfHFEJh0WBtMqo-1vbXqw1vHOMM7mcLVcDr-kITwpfTwQzuMWiGCnHLX8w499mgcWNAknnn7bjK0jcJaW2WgYNJj9yyMdRpwB2FNbWX_9wwddPSaPYvAIl-34TsmRqXvkpC0nueuRBzfxoLxHBrOWknp3DvM9wqo5hwHM9mTVuydkO3crt2wc_ptqDFxfw6-fgFzUIBuQgFAeswYf2cJs7TApz3_GX2JHKFJwFqbeo20cngBgSitMsDpR7e7kBVyCH1ukZsXuoaNAeUpurz7OJ9MklmJINPq4xFBOWeG3PqPUIkEQU1wyqkvLq3GKAGzFcG-Jvs3kiPatjMqtLEY2rTIj7fgZOa5dbV4QsJL7kMayTPtQLFemUFyn3BqtylSOtO6TQScOoSNPOZbL-C78fiXITbRy6xO4b7hqqTkOm7zv5Cn-0irhHcZh47edxIVfYzhtsjZu24iMM4aUAXneJ89bVbjvcewf8bzM_GiibohoBRqh75pvwmQIZsYOXv7PaF6Rh_hiyyn5mhxv1ltz5uOfjXoTFPw34qkBRA
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELaWRTwuCMqrPAcJekAb2qSOkyBxWC2sWna7qkRX6s3rODYqYpOqaYV64T8h_ge_iZnE2YIqDhz2FiWWbXnGM5_jmW8Ye8l9LWwWaa8fa-3xwOKeS7n2_Ax9NVepjatyPqMTMTjlH6fhdIf9bHJhKKzS2f7aplfW2r3putXszmez7ie_gicJ4oHqPm7qIiuPzPobntvKd8P3KORXQXD4YXIw8FxpAU-TzfYMj7iIEcr3fEuENyKNlOA6sVHW9ymhOBV0ViJbbULKXs1MGloV96yfBUbZPvZ7hV3laC6obMKb75u4EqqgUl2x4jmdpucydXkS9LrVlhH_coHbELfKJMqtyj__4fQOb7NbDq3Cfr0gd9iOyVvsWl2_ct1i10fuZr7FOuOaA3u9B5NNSle5Bx0Yb9ix13fZalLMi1lZ0M-w0sBwCL9-AJFfgypBAeUOmQUglIbxoqAoQOwGH2kg0iEoLAzQhS4LunKgGFo4oHJIeXGu3sI-4NwcFywNDw3nyj12eikCus928yI3DxlYFSGGsiLQiP3C1MRppP3IGp0mvupp3WadRhxSO2J0qs_xVeIBqZKbrOXWZnDRcF5zgWw3ed3IU_6lxhI91HbjF43EJW5qWjaVm2JVyiASgjgKwrDNHtSqcDFiHz9FYRLgbJxuSGd2SqnPyy_SBJQ9TQM8-p_ZPGc3BpPRsTwenhw9Zjepk5rQ8gnbXS5W5imCr2X6rFJ2YGeXvbt-A86tO9Y
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Topoisomerase+%E2%85%A1%CE%B1+Gene+as+a+Marker+for+Prognostic+Prediction+of+Hepatocellular+Carcinoma%3A+A+Bioinformatics+Analysis&rft.jtitle=Chinese+medical+sciences+journal&rft.au=Lu%2C+Jin&rft.au=An%2C+Shao-Guang&rft.au=Ma%2C+Jun-Jie&rft.au=Yang%2C+Yue&rft.date=2022-12-31&rft.issn=1001-9294&rft.volume=37&rft.issue=4&rft.spage=331&rft_id=info:doi/10.24920%2F004006&rft.externalDBID=NO_FULL_TEXT
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fcmsj-e%2Fcmsj-e.jpg